Stemson aims to restore human hair growth by using a patient’s own cells to generate hair follicles.Allergan Aesthetics is a world-leading medical aesthetics company. Fortunis Capital, a London-based venture capital firm, is committed to continuing support of Stemson’s regenerative cell therapy to treat hair loss. Fortunis Capital’s new Impact Fund intends to invest in companies, such as Stemson, who offer significant social or environmental benefit.
Commenting on the investment Sir Andrew Ross, the director of investments at Fortunis Capital said: “We believe that Stemson has the team, technology and the tools in place to develop a therapy capable of solving the hair loss problem for millions of people in need.
“Stemson’s novel cell therapy approach to treat hair loss has game-changing potential. Their experienced management team is poised to elevate its proprietary regenerative cell therapy method as it begins the next phase of its preclinical program.”